The potential discovery of downstream effectors of Bmi-1, which could also lead to improved detection of cancers—perhaps an early application of RNAi Bmi-1 inhibition as a preventative measure in a patient identified as high risk—might hold just as much potential in developing future therapies. Here, BMI1 is linked to cancer.